The Second Shot That Missed: What Agios' Tebapivat Failure Means for the Sickle Cell Race

Agios Pharmaceuticals had a plan. After its lead drug mitapivat delivered mixed Phase 3 results in sickle cell disease last year, the Cambridge-based biotech was counting on tebapivat, a next-generation pyruvate kinase activator, to serve as a backup narrative and a longer-term franchise anchor. On Tuesday, that plan collapsed. Agios announced it would discontinue tebapivat in sickle cell disease after Phase 2 data showed the drug failed to demonstrate a meaningful dose-response relationship and offered no clear differentiation from competitors. Shares fell as much as 14% on the news.

The Phase 2 trial enrolled 59 patients aged 16 and older with sickle cell disease, randomizing them to one of three once-daily doses of tebapivat (2.5 mg, 5.0 mg, or 7.5 mg) or placebo over a 12-week double-blind period. The primary endpoint was hemoglobin response. The results were, to put it plainly, a mess: response rates of 43.8% at 2.5 mg, 47.1% at 5 mg, and 29.4% at the highest 7.5 mg dose, compared to 33.3% in the placebo arm. Not only did the highest dose perform worst, but the numbers failed to clear Agios' own internal bar for continued development. The company said the profile was not meaningfully differentiated relative to other PK activators in the space.

The Benchmark That Mattered

That phrase, "other PK activators," is doing a lot of work. The most relevant comparison is Novo Nordisk's etavopivat, which reported Phase 3 HIBISCUS trial data earlier this year showing a 48.7% hemoglobin response rate after 24 weeks, alongside a 27% reduction in vaso-occlusive crises, the painful and dangerous episodes that define the disease burden for patients. Novo has said it plans to file for FDA approval in the second half of 2026. Against that backdrop, tebapivat's Phase 2 numbers were not just underwhelming; they were disqualifying.

Agios' own mitapivat, meanwhile, achieved a 40.6% hemoglobin response in its Phase 3 RISE UP trial. That drug is currently under FDA priority review with a PDUFA date of November 1, 2026. Mitapivat is already approved in two other indications, marketed as Pyrukynd for pyruvate kinase deficiency and as Aqvesme for anemia in patients with alpha- or beta-thalassemia. The sickle cell approval, if it comes, would represent a meaningful commercial expansion. But the tebapivat discontinuation removes what analysts had called Agios' "second shot on goal" in the indication, concentrating risk squarely on mitapivat's regulatory outcome and commercial execution.

A Crowded Class With a Rising Bar

The PK activator story in sickle cell disease is a useful case study in how competitive dynamics can reshape the value of a drug class in real time. When Agios first demonstrated that activating pyruvate kinase could improve red blood cell function and reduce hemolysis in sickle cell patients, it was a genuinely novel mechanism. But the class has since attracted multiple entrants, and the bar for differentiation has risen sharply. Novo's etavopivat data, with its combination of hemoglobin response and vaso-occlusive crisis reduction, has set a new standard that tebapivat simply could not meet.

This matters beyond Agios. Sickle cell disease affects approximately 100,000 Americans, the vast majority of whom are Black, and the disease has historically been underfunded and underserved relative to its burden. The recent wave of therapeutic development, including gene therapies, anti-sickling agents, and now oral PK activators, represents a genuine inflection point for patients. But the proliferation of candidates also means that the market will not accommodate every entrant, and drugs that cannot demonstrate clear differentiation will be cut, as tebapivat was.

What Comes Next for Agios

Analysts at Leerink Partners noted that tebapivat was not included in their financial model, so the discontinuation does not change their estimates for Agios. Truist analysts were more pointed, writing that the axing removes a narrative enricher for longer-term franchise durability and increases concentration risk on mitapivat at a time when the competitive bar continues to rise. Both firms, however, maintained that the core thesis for Agios rests on mitapivat's November FDA decision and the company's ability to execute commercially in thalassemia, where the drug is already approved.

There is also the broader pipeline to consider. Agios is developing AG-181 for phenylketonuria and AG-236 for polycythemia vera, and the company has signaled openness to business development. The tebapivat failure does not change the fundamental science of PK activation, but it does serve as a reminder that next-generation iterations of a mechanism do not automatically inherit the promise of their predecessors. In drug development, being second in a class is hard enough. Being third, without a compelling differentiation story, is nearly impossible.

For patients with sickle cell disease, the discontinuation is a footnote. The more consequential question is whether mitapivat earns its approval in November, and whether Novo's etavopivat filing later this year opens a new chapter in oral treatment for a disease that has waited far too long for options.